OJGas  Vol.3 No.2 , May 2013
Lack of estrogen receptors expression in malignant and pre-malignant colorectal lesions in Egyptian patients
ABSTRACT

Background: incidence of Colorectal cancer (CRC) is increasing globally. In Egypt, CRC ranks the sixth most common cancer in males and the fifth in females. Aim: To assess the expression of estrogen receptors (alpha and beta) in pre-malignant (adenomatous polyps and IBD), malignant colorectal lesions and normal colonic mucosa in group of Egyptian patients. Methods: This prospective study was done on 45 patients presenting with colonic symptoms, patients were divided into four groups; 15 CRC patients, 10 patients with adenomatous polyps, 10 IBD patients and 10 patients in the control group. Patients subjected to: Stool analysis, FOBT, CBC, CEA, Abdominal ultrasound & colonoscopy and biopsy (number = 80), Pathological, immunohistochemistry and RT- PCR quantification of ERα and ERβ were done. Results: Mean age: 39.2 (12 - 73), gender: M/F: 28/17. Bleeding per rectum was the commonest presentation; 29/45 (64.4%). CEA was significantly elevated in the CRC group compared with other studied groups (1692 mg/L vs. 4.0, 4.0 and 4.4 mg/L). Ultrasonography of the studied patients showed that metastatic CRC: 3/15 (20%); Colonic wall thickening: 5/15 (33.3%), 1/10 showed colonic polypoidal lesions in adenomatous polyps groups, in IBD group: 4/10 (40%) showed colonic and ileocecal thicknening. All the studied patients showed negative results for estrogen receptors (alpha and beta) by the use of immunohistochemistry staining and RT-PCR technique. Conclusion: Role of estrogen receptors in the colonic mucosa, precancerous and colorectal cancer is doubtful, contradictory results with some literature data could be due to racial and genetic difference in the studied population.


Cite this paper
Said, M. , Khairy, M. , El-Hendawy, A. , Khalf, O. , Abdelbary, M. , Saadi, Y. and Yosry, A. (2013) Lack of estrogen receptors expression in malignant and pre-malignant colorectal lesions in Egyptian patients. Open Journal of Gastroenterology, 3, 155-163. doi: 10.4236/ojgas.2013.32026.
References
[1]   Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J. and Thun, M.J. (2009) Cancer statistics. CA: A Cancer Journal for Clinicians, 59, 225-249.

[2]   World Health Organization (2006) Cancer. Fact Sheet (No. 297), Geneva. http://www.who.int/mediacentre/factsheets/fs297/en/print.html

[3]   National Cancer Institute (2002) Administrative and statistical report for NCI, 2002-2008. www.nci.edu.eg

[4]   National Cancer Institute (2008) Administrative and statistical report for NCI. http://www.nci.edu.eg

[5]   Leung, Y.K., Mak, P., Hassan, S., et al. (2006) Estrogen receptor (ER)-β isoforms: A key to understanding ER-β signaling. Proceedings of the National Academy of Sciences of the United States of America, 103, 13162-13167. doi:10.1073/pnas.0605676103

[6]   Campbell-Thompson, M., Lynch, I. and Bhardwaj, B. (2001) Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Research, 61, 632-640.

[7]   Mueller, S.O. and Korach, K.S. (2001) Estrogen receptors and endocrine diseases: Lessons from estrogen receptor knockout mice. Current Opinion in Pharmacology, 1, 613-619.

[8]   Björnström, L. and Sjöberg, M. (2005) Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Molecular Endocrinology, 19, 833-842.

[9]   Konstantinopoulos, P.A., Kominea, A., Vandoros, G., et al. (2003) Oestrogen receptor β (ERβ) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. European Journal of Cancer, 39, 1251-1258. doi:10.1016/S0959-8049(03)00239-9

[10]   Harnish, D., Albert, L., Leathurby, Y. et al. (2004) Beneficial effects of estrogen treatment in the HLA-B27 transgenic rat model of inflammatory bowel disease. American Journal of Physiology Gastrointestinal and Liver Physiology, 286, 118-125. doi:10.1152/ajpgi.00024.2003

[11]   Gustfsson, J.-Å. (2006) ERβ scientific visions translate to clinical uses. Climacteric, 9, 156-160. doi:10.1080/14689360600734328

[12]   Harris, H.A. (2007) Estrogen receptor-β: Recent lessons from in vivo studies. Molecular Endocrinology, 21, 1-13. doi:10.1210/me.2005-0459

[13]   Galluzzo, P., Caiazza, F., Moreno, S., et al. (2007) Role of ERbeta palmitoylation in the inhibition of human colon cancer cell proliferation. Endocrine-Related Cancer, 14, 153-167. doi:10.1677/ERC-06-0020

[14]   Di Leo, A., Barone, M., Maiorano, E., et al. (2008) ERbeta expression in large bowel adenomas: Implications in colon carcinogenesis. Digestive and Liver Disease, 40, 260-266. doi:10.1016/j.dld.2007.10.018

[15]   Fletcher, R.H. (2000) Screening for colorectal cancer: Strategies in patients at average risk. http://www.uptodate.com/contents/screening-for-colorectal-cancer-strategies-in-patients-at-average-risk

[16]   National Cancer Institute (2009) Cancer. http://www.cancer.gov/cancertopics/commoncancers

[17]   Campbell-Thompson, M., Lynch, I. and Bhardwaj, B. (2001) Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Research, 61, 632-640.

[18]   Konstantinopoulos, P.A., Kominea, A., Vandoros, G., et al. (2003) Oestrogen receptor β (ERβ) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. European Journal of Cancer, 39, 1251-1258. doi:10.1016/S0959-8049(03)00239-9

[19]   Xie, L.Q., Yu, J.P. and Luo, H.S. (2004) Expression of estrogen receptor β in human colorectal cancer. World Journal of Gastroenterology, 10, 214-217.

[20]   Ferlay, J., Bray, F., Pisani, P., et al. (2005) Cancer incidence, mortality and prevalence worldwide. CA: A Cancer Journal for Clinicians, 55, 74-108.

[21]   El Attar, I. (2005) Colo-rectal cancer: Magnitude of the problem. Annual cancer. Conference of the Egyptian Cancer Society, Danish Cancer Society & Aarhus University Hospital, Cairo, 9-11 February.

[22]   Mc Leod, H. and Murray, G. (1999) Tumor markers of prognosis in colorectal cancer. British Journal of Cancer, 79, 191-203. doi:10.1038/sj.bjc.6690033

[23]   Bond, J. (2000) Colorectal cancer update. Prevention, screening, treatment, and surveillance for high risk groups. Medical Clinics of North America, 84, 1163-1182. doi:10.1016/S0025-7125(05)70281-9

[24]   Zakaria, M.S., Hashem, A., Abdelbary, M.S., et al. (2006) The pattern of colonic diseases in Egypt: A colonoscopic study. Arab Journal of Gastroenterology, 7, 53-58.

[25]   Winawer, S.J., Fletcher, R., Rex, D., et al. (2003) Colorectal cancer screening and surveillance: Clinical guidelines and rationale-Update based on new evidence. Gastroenterology, 124, 544. doi:10.1053/gast.2003.50044

[26]   Deans, G.T., Patterson, C.C., Parks, T.G., et al. (1994) Colorectal carcinoma: Importance of clinical and pathological factors in survival. Annals of the Royal College of Surgeons of England, 76, 59-64.

[27]   Kanazawa, T., Watanabe, T., Kazama, S., et al. (2002) Poorly differentiated adenocarcinoma and mucinous carcinoma of the colon and rectum show higher rates of loss of heterozygosity and loss of E-cadherin expression due to methylation of promoter region. International Journal of Cancer, 102, 225-229. doi:10.1002/ijc.10690

[28]   Slattery, M.L., Samowitz, W.S. and Holden, J.A. (2000) Estrogen and progesterone receptors in colon tumors. American Journal of Clinical Pathology, 113, 364-368. doi:10.1309/5MHB-K6XX-QV50-PCJQ

[29]   Ekem, T.E., Bahadir, B., Gun, B.D., et al. (2008) Colorectal carcinomas: Clinicopathologic investigation, correlation with expression of estrogen and progesterone receptors. Turkish Journal of Cancer, 38, 118-122.

[30]   Dawson, P., Shousha, S., Blair, S., et al. (1990) Oestrogen receptors in colorectal carcinoma. Journal of Clinical Pathology, 43, 149-151. doi:10.1136/jcp.43.2.149

[31]   Foley, E.F., Jazaeri, A.A., Shupnik, M.A., et al. (2000) Selective loss of estrogen receptor β in malignant human colon. Cancer Research, 60, 245-248.

[32]   Qiu, Y., Waters, C., Lewis, A., et al. (2002) Oestrogeninduced apoptosis in colonocytes expressing oestrogen receptor beta. Journal of Endocrinology, 174, 369-377. doi:10.1677/joe.0.1740369

[33]   Wada-Hiraike, O., Imamov, O., Hiraike, H., et al. (2006) Role of estrogen receptor β in colonic epithelium. Proceedings of the National Academy of Sciences of the United States of America, 103, 2959-2964. doi:10.1073/pnas.0511271103

[34]   Witte, D., Chirala, M., Younes, A., et al. (2001) Estrogen receptor beta is expressed in human colorectal adenocarcinoma. Human Pathology, 32, 940-944. doi:10.1053/hupa.2001.27117

[35]   Galluzzo, P., Caiazza, F., Moreno, S., et al. (2007) Role of ERbeta palmitoylation in the inhibition of human colon cancer cell proliferation. Endocrine-Related Cancer, 14, 153-167. doi:10.1677/ERC-06-0020

[36]   Concolino, G., Arrabito, G., Buonomo, O., et al. (1986) Nuclear steroid receptors and dysplasia in adenomatous polyps of the colon as markers of high risk for malignant transformation. Cancer Detection and Prevention Journal, 9, 477-484.

[37]   Di Leo, A., Barone, M., Maiorano, E., et al. (2008) ERbeta expression in large bowel adenomas: Implications in colon carcinogenesis. Digestive and Liver Disease, 40, 260-266. doi:10.1016/j.dld.2007.10.018

[38]   Zakaria, M.S., Abdel-Bary, M.S., Said, M., Yosry, Ay., Seif, M. and Hindawy A. (2007) Evaluation of estrogen receptors in malignant and premalignant colorectal lesions. Egyptian journal of Medical Sciences, 28, 12.

[39]   Shen, R.L., Tao, L.H., Xu, Y.Q., Chang, S., Van Brocklyn, J. and Gao, J.-X. (2009) Reversibility of aberrant global DNA and estrogen receptor-α gene methylation distinguishes colorectal precancer from cancer. International Journal of Clinical and Experimental Pathology, 2, 21-33.

 
 
Top